Vemircopan
- Generic Name
- Vemircopan
- Drug Type
- Small Molecule
- Chemical Formula
- C29H28BrN7O3
- CAS Number
- 2086178-00-7
- Unique Ingredient Identifier
- HN6I4K50QB
A Study of the Cardiac Effects of ALXN2050 in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04660890
- Locations
- 🇺🇸
Clinical Trial Site, Tempe, Arizona, United States
Study of ALXN2050 in Participants With Renal Impairment
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04623710
- Locations
- 🇺🇸
Clinical Trial Site, Orlando, Florida, United States
Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT04170023
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath